ArticleVaccines2022

Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine.

Andrea Galitzia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.